Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 1997

View Archived Issues

Gd-Tex in phase Ib: safety profile and maximum tolerated dose

Novel class III antiarrhythmic agents described by Merck & Co.

Taisho reports new macrolides termed "acylides"

Nonexclusive licensing opportunity in HCV protease inhibitor research announced by Chiron

SDD drug delivery system available for licensing from Bioglan

SS-Cream evaluated in subjects with premature ejaculation

Safety and efficacy data for INVICORP reported at impotence meeting

MOMP DNA immunization for chlamydial infections

Efficacy of cholesterol biosynthesis inhibitor demonstrated in dogs

GS-4104 (Ro-64-0796): safety and pharmacokinetics in humans

Cytokine synthesis inhibitor protects against polymicrobial sepsis in animal model

Clinical pharmacokinetic study of panomifene described

BB-2983 development discontinued

Behring Diagnostics-Dade merger complete

Profile of a monobactam beta-lactamase inhibitor

Block Drug to promote Duract to U.S. dentists

Kyowa Hakko's cytostatic agents progress in U.S. clinical trials

Korean research institute synthesizes potent DNA gyrase inhibitors

Rhone-Poulenc completes tender offer for Rhone-Poulenc Rorer

Celgene initiates clinical trials for novel TNF-alpha inhibitors

Guilford issued U.S. patent on NAALADase inhibitors

New antifungal antibiotic with sphingosine-like lipid moiety

Mitsui Toatsu's antiplatelet agent slated to enter clinical testing

Abbott prepares and evaluates tetracyclic ketolides as antibacterials

Mitsui Toatsu's hGH enters clinical testing this month

Genentech returns rights to IDEC-Y2B8 to IDEC

Spine-Tech and Sulzer Orthopedics Biologics announce alliance

Asahi Chemical's AP-521 in clinical development in three countries

Nasonex Nasal Spray cleared for marketing in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...